InSilico Medicine Cayman TopCo is an artificial intelligence-based biotechnology company focused on drug discovery and development. It leverages generative AI through its Pharma.AI platform, an end-to-end software and automation solution that enhances pharmaceutical research productivity by identifying novel drug targets and generating molecules for various diseases. The company targets therapeutic areas including cancer, fibrosis, immunity, central nervous system disorders, infectious diseases, autoimmune conditions, and aging-related diseases. Operating a project-based business model, it generates revenue from out-licensing agreements and collaborations with pharmaceutical and biotechnology partners. InSilico Medicine Cayman TopCo maintains facilities in Hong Kong, the United States, the United Kingdom, and Mainland China, supporting its international drug development efforts. Founded in 2014 and headquartered in the New Territories, Hong Kong, it plays a key role in accelerating AI-driven innovations in the healthcare and technology sectors.